The Hoya and Santen-backed glaucoma treatment developer has closed its series C round at $33.9m and has now raised almost $50m in total.
InnFocus, the US-based developer of a glaucoma drainage system, has closed a $33.9m series C round featuring optical product manufacturer Hoya Corporation and pharmaceutical firm Santen Pharmaceutical.
In addition to the Japan-based corporates, investors in the round also included Saints Capital Everest and Crown Venture Fund.
InnFocus is working on a drainage system called MicroShunt to treat patients suffering from the eye condition glaucoma. The device is expected to enter the final phase of clinical testing next month, and the…
